{"id":49,"date":"2019-05-27T07:29:07","date_gmt":"2019-05-27T07:29:07","guid":{"rendered":"https:\/\/spaceraceit.com\/wp\/growth\/?p=49"},"modified":"2021-03-12T13:50:20","modified_gmt":"2021-03-12T13:50:20","slug":"temozolomide-and-pituitary-tumors","status":"publish","type":"post","link":"https:\/\/leonortizgomez.com\/en\/publications\/temozolomide-and-pituitary-tumors\/","title":{"rendered":"Temozolomide and Pituitary Tumors"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"49\" class=\"elementor elementor-49\" data-elementor-settings=\"[]\">\n\t\t\t\t\t\t<div class=\"elementor-inner\">\n\t\t\t\t\t\t\t<div class=\"elementor-section-wrap\">\n\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-396c149c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"396c149c\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t\t\t<div class=\"elementor-row\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4908d0ba\" data-id=\"4908d0ba\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-column-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-27c22ae6 elementor-widget elementor-widget-text-editor\" data-id=\"27c22ae6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-text-editor elementor-clearfix\"><div class=\"JournalAbstract\">\r\n<h1>Current Understanding, Unresolved Issues, and Future Directions<\/h1>\r\n<div><\/div>\r\n<div class=\"authors\">Luis V. Syro<sup>1<\/sup>*, Fabio Rotondo<sup>2<\/sup>, Mauricio Camargo<sup>3<\/sup>, Leon D. Ortiz<sup>4<\/sup>, Carlos A. Serna<sup>5<\/sup> and Kalman Kovacs<sup>2<\/sup><\/div>\r\n<ul class=\"notes\">\r\n \t<li><sup>1<\/sup>Department of Neurosurgery, Hospital Pablo Tobon Uribe and Clinica Medellin, Medellin, Colombia<\/li>\r\n \t<li><sup>2<\/sup>Department of Laboratory Medicine, Division of Pathology, St. Michael\u2019s Hospital, University of Toronto, Toronto, ON, Canada<\/li>\r\n \t<li><sup>3<\/sup>Genetics, Regeneration and Cancer Laboratory, Universidad de Antioquia, Medellin, Colombia<\/li>\r\n \t<li><sup>4<\/sup>Division of Neuro-oncology, Instituto de Cancerolog\u00eda, Clinica Las Americas, Pharmacogenomics, Universidad CES, Medellin, Colombia<\/li>\r\n \t<li><sup>5<\/sup>Laboratorio de Patologia y Citologia Rodrigo Restrepo, Department of Pathology, Clinica Las Am\u00e9ricas, Universidad CES, Medellin, Colombia<\/li>\r\n<\/ul>\r\nTemozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.\r\n\r\n<\/div>\r\n<div class=\"JournalFullText\">\r\n<h2>Introduction<\/h2>\r\n<p class=\"mb0\">Since its development, temozolomide (TMZ), a monofunctional alkylating agent, has shown remarkable efficacy in the treatment of a variety of solid tumors and it has become an essential component of adjuvant therapy for the most frequent adult brain tumor type, glioblastoma multiforme (GBM) (<a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2018.00318\/full#B1\">1<\/a>, <a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2018.00318\/full#B2\">2<\/a>). Its unique chemical structure and pharmacokinetic properties confer distinctive advantages over other alkylating agents. In 2006, TMZ began to be used for the treatment of aggressive pituitary adenomas and pituitary carcinomas (<a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2018.00318\/full#B3\">3<\/a>\u2013<a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2018.00318\/full#B5\">5<\/a>). In this paper, we review the mechanism of action of TMZ, the deoxyribonucleic acid (DNA) repair systems triggered after its administration, the current understanding of TMZ activity, and the unresolved issues of its clinical use in pituitary tumors.<\/p>\r\n<a class=\"fullscreen-mode\" href=\"https:\/\/leonortizgomez.com\/en\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL2xlb25vcnRpemdvbWV6LmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMS8wMy9mZW5kby0wOS0wMDMxOC5wZGYmc2V0dGluZ3M9MTExMTExMTExMTExMTExMTEwMCZsYW5nPWVuLVVT#page=&#038;zoom=auto&#038;pagemode=none\" target=\"_blank\">Fullscreen Mode<\/a><br><iframe loading=\"lazy\" width=\"1200\" height=\"1500\" src=\"https:\/\/leonortizgomez.com\/en\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL2xlb25vcnRpemdvbWV6LmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMS8wMy9mZW5kby0wOS0wMDMxOC5wZGYmc2V0dGluZ3M9MTExMTExMTExMTExMTExMTEwMCZsYW5nPWVuLVVT#page=&#038;zoom=auto&#038;pagemode=none\" title=\"\"><\/iframe>\r\n\r\n<\/div>\r\n&nbsp;\r\n\r\n&nbsp;<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"\n<p>\t\t\t\tTemozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. \t\t\t\t\t\t<\/p>\n","protected":false},"author":1,"featured_media":1421,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-49","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications"],"_links":{"self":[{"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/posts\/49","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/comments?post=49"}],"version-history":[{"count":9,"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/posts\/49\/revisions"}],"predecessor-version":[{"id":1534,"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/posts\/49\/revisions\/1534"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/media\/1421"}],"wp:attachment":[{"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/media?parent=49"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/categories?post=49"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leonortizgomez.com\/en\/wp-json\/wp\/v2\/tags?post=49"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}